Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: A systematic review and meta-analysis

Oncotarget

Volumn 7, Issue 47, 2016, Pages 76693-76703

  Wang, Jue ^a   Yin, Jun ^b   Yang, Qing ^a   Ding, Feng ^a,c   Chen, Xiao ^a   Li, Bingjie ^d   Tian, Xingsong ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Jinan Center Hospital   (China)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; HER4 ErbB 4; Marker; Meta analysis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; TRASTUZUMAB; ERBB4 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CELL NUCLEUS; CYTOPLASM; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; HER2 POSITIVE BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; FEMALE; GENE EXPRESSION; GENETICS; META ANALYSIS; METABOLISM; MORTALITY; PROGNOSIS; PROTEIN TRANSPORT; PUBLISHING; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; PROGNOSIS; PROTEIN TRANSPORT; PUBLICATION BIAS; RECEPTOR, ERBB-4; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84998953418     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12485     Document Type: Article

References (46)

1. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012.
2. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. Journal of mammary gland biology and neoplasia. 2008; 13:215-223.
3. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Current opinion in cell biology. 2007; 19:124-134.
4. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd and Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:8933-8938.
5. Maatta JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Molecular biology of the cell. 2006; 17:67-79.
6. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K. Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer research. 2005; 65:1384-1393.
7. Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM. Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer research. 2007; 67:6760-6767.
8. Alaoui-Jamali MA, Song DJ, Benlimame N, Yen L, Deng X, Hernandez-Perez M, Wang T. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer research. 2003; 63:3764-3774.
9. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. Journal of Biological Chemistry. 1996; 271:30897-30903.
10. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growthpromoting autocrine signal in breast tumor cells. Cancer research. 2006; 66:7991-7998.
11. Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA, Jr., McCall W, Sgagias MK, Cowan KH, Earp HS, 3rd. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Molecular and cellular biology. 2006; 26:6412-6424.
12. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS, 3rd. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Molecular and cellular biology. 2001; 21:4265-4275.
13. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JM. HER4 in breast cancer: comparison of antibodies against intra-and extra-cellular domains of HER4. Breast cancer research. 2006; 8:R19.
14. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clinical Cancer Research. 2005; 11:2163-2168.
15. Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y, Tamura K. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. Annals of oncology. 2014; 25:1973-1979.
16. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y, Iwase H. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast cancer. 2014; 21:472-481.
17. Syed BM, Green AR, Paish EC, Soria D, Garibaldi J, Morgan L, Morgan DA, Ellis IO, Cheung KL. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. British journal of cancer. 2013; 108:1042-1051.
18. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 2005; 103:1770-1777.
19. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast cancer research: BCR. 2008; 10:R2.
20. Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast cancer research: BCR. 2009; 11:R11.
21. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. The Journal of pathology. 2002; 196:17-25.
22. Fuchs IB, Siemer I, Buehler H, Schmider A, Henrich W, Lichtenegger W, Schaller G, Kuemmel S. Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer research. 2006; 26:4397-4401.
23. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. British journal of cancer. 2004; 91:1532-1542.
24. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. The Journal of pathology. 2003; 200:290-297.
25. Zhang L, Liu B, Yu SY, Meng Y, Zhou JD, Wu JC. Expression and clinical significance of HER4 in breast carcinoma. Acta Universitatis Medicinalis Nanjing (Natural Science). 2011; 31: 1196-1207.
26. Nafi S, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li J-L, Bridges E. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 2014; 5:5934-5949. doi:10.18632/oncotarget.1904.
27. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. International journal of cancer. 2003; 106:758-765.
28. Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Breast cancer. 2015; 22:292-299.
29. Aubele M, Walch AK, Ludyga N, Braselmann H, Atkinson MJ, Luber B, Auer G, Tapio S, Cooke T, Bartlett JM. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. British journal of cancer. 2008; 99:1089-1095.
30. Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat J-P. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clinical Cancer Research. 2000; 6:4217-4225.
31. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. British journal of cancer. 2007; 96:801-807.
32. Badovinac-Crnjevic T, Jakic-Razumovic J, Podolski P, Plestina S, Sarcevic B, Munjas R, Vrbanec D. Significance of epidermal growth factor receptor expression in breast cancer. Medical oncology. 2011; 28:S121-128.
33. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. The American journal of pathology. 2009; 175:1802-1809.
34. McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast cancer research and treatment. 2010; 122:105-110.
35. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer research. 2008; 68:6387-6395.
36. Fujiwara S, Hung M, Yamamoto-Ibusuk C, Yamamoto Y, Yamamoto S, Tomiguchi M, Takeshita T, Hayashi M, Sueta A, Iwase H. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2-breast cancer. Oncotarget. 2014; 5:3919-3930. doi: 10.18632/oncotarget.2002.
37. Machleidt A, Buchholz S, Diermeier-Daucher S, Zeman F, Ortmann O, Brockhoff G. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients. BMC cancer. 2013; 13:437.
38. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert A-P, Vallot F, Lafitte J-J, Sculier J-P. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a metaanalysis. European Respiratory Journal. 2001; 18:705-719.
39. Vidal GA, Naresh A, Marrero L, Jones FE. Presenilindependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. The Journal of biological chemistry. 2005; 280:19777-19783.
40. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer research. 2006; 66:6412-6420.
41. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. The Journal of cell biology. 2004; 167:469-478.
42. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS, 3rd. The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Molecular biology of the cell. 2006; 17:4118-4129.
43. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. Journal of Biological Chemistry. 2000; 275:8641-8649.
44. Nielsen TO, Sorensen S, Dagnaes-Hansen F, Kjems J, Sorensen BS. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. British journal of cancer. 2013; 108:2291-2298.
45. Wang Y, Zeng T. Response to: Practical methods for incorporating summary time-to-event data into metaanalysis. Trials. 2013; 14:391.
46. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. Journal of clinical epidemiology. 2001; 54:1046-1055.